Tags

Type your tag names separated by a space and hit enter

Present status of chemotherapy for tuberculosis.
Rev Infect Dis 1989 Mar-Apr; 11 Suppl 2:S347-52RI

Abstract

For the treatment of smear-positive pulmonary tuberculosis, short-course chemotherapy of 6 months' duration (with the four-drug combination of isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin given daily for a 2-month initial intensive phase followed by a 4-month daily continuation phase with isoniazid and rifampin) is as effective and as acceptable as the standard 9-month daily course of therapy (with isoniazid, rifampin, and ethambutol given for a 2-month initial intensive phase followed by a 7-month daily continuation phase with isoniazid and rifampin). The duration of short-course chemotherapy cannot be further reduced for smear-negative and culture-positive or smear-negative and culture-negative pulmonary tuberculosis or for extrapulmonary tuberculosis. Isoniazid has been demonstrated to be active as prophylactic therapy for tuberculosis at a daily dose of 300 mg (5-10 mg/kg in children) for 6-12 months. Prophylaxis of 2 months' duration with daily administration of isoniazid, rifampin, and pyrazinamide may be as effective as prophylactic therapy with isoniazid of 12 months' duration.

Authors+Show Affiliations

Laboratoire Central de Bactériologie-Virologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2652251

Citation

Grosset, J H.. "Present Status of Chemotherapy for Tuberculosis." Reviews of Infectious Diseases, vol. 11 Suppl 2, 1989, pp. S347-52.
Grosset JH. Present status of chemotherapy for tuberculosis. Rev Infect Dis. 1989;11 Suppl 2:S347-52.
Grosset, J. H. (1989). Present status of chemotherapy for tuberculosis. Reviews of Infectious Diseases, 11 Suppl 2, pp. S347-52.
Grosset JH. Present Status of Chemotherapy for Tuberculosis. Rev Infect Dis. 1989;11 Suppl 2:S347-52. PubMed PMID: 2652251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Present status of chemotherapy for tuberculosis. A1 - Grosset,J H, PY - 1989/3/1/pubmed PY - 1989/3/1/medline PY - 1989/3/1/entrez SP - S347 EP - 52 JF - Reviews of infectious diseases JO - Rev. Infect. Dis. VL - 11 Suppl 2 N2 - For the treatment of smear-positive pulmonary tuberculosis, short-course chemotherapy of 6 months' duration (with the four-drug combination of isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin given daily for a 2-month initial intensive phase followed by a 4-month daily continuation phase with isoniazid and rifampin) is as effective and as acceptable as the standard 9-month daily course of therapy (with isoniazid, rifampin, and ethambutol given for a 2-month initial intensive phase followed by a 7-month daily continuation phase with isoniazid and rifampin). The duration of short-course chemotherapy cannot be further reduced for smear-negative and culture-positive or smear-negative and culture-negative pulmonary tuberculosis or for extrapulmonary tuberculosis. Isoniazid has been demonstrated to be active as prophylactic therapy for tuberculosis at a daily dose of 300 mg (5-10 mg/kg in children) for 6-12 months. Prophylaxis of 2 months' duration with daily administration of isoniazid, rifampin, and pyrazinamide may be as effective as prophylactic therapy with isoniazid of 12 months' duration. SN - 0162-0886 UR - https://www.unboundmedicine.com/medline/citation/2652251/Present_status_of_chemotherapy_for_tuberculosis_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -